Liver Cancer Therapeutics Market Trends

Growth Drivers

Growing prevalence of liver cancer
Rise in incidence of hepatitis B infection in developing countries
Increasing R&D activities and advancement in cancer therapeutics

Challenges

High cost and side effects related to certain liver cancer therapies
Limitations in treatment options with several therapies in clinical trial stage

Liver Cancer Therapeutics Market: Key Insights

Base Year	2023
Forecast Year	2024–2036
CAGR	18.4%
Base Year Market Size (2023)	USD 2.99 billion
Forecast Year Market Size (2036)	USD 26.87 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of liver cancer therapeutics is estimated at USD 3.43 billion.

Liver Cancer Therapeutics Market size was over USD 2.99 billion in 2023 and is anticipated to reach USD 26.87 billion by 2036, witnessing around 18.4% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of liver cancer, rise in incidence of hepatitis B infection in developing countries, and increasing R&D activities and advancement in cancer therapeutics will impel the market growth.

North America region is expected to hold largest industry share by 2036, owing to high awareness about liver cancer, presence of well-established healthcare infrastructure, and easy drug availability.

The major players in the market are Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Bayer AG, Zymeworks Inc., F. Hoffmann-La Roche Ltd., Celsion Corporation, Eli Lilly and Company, AstraZeneca, and others.

Liver Cancer Therapeutics Market Trends